At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
BZ371Adrug
Likely dose
BZ371A 1.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Clinical Trial Study to Evaluate Pharmacokinetics and Safety Profile of BZ371A in a Gel Formulation, Applied on Healthy Men and Women Genitals
In Brief
A Phase 1 clinical trial evaluating BZ371A for Erectile Dysfunction Following Radical Prostatectomy and 3 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
CountriesBrazil
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartNov 2022
Primary CompletionNov 2022
TodayJul 2026
First PostedApr 18, 2022
Enrollment StartNov 16, 2022
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 14 daysPosted 4.2 years ago
Interventions
BZ371Adrug
Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.